THERAVANCE BIOPHARMA INC (TBPH)
KYG8807B1068 - Common Stock
| MRQ (2024-3-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 99.97M | 102.43M | 298.20M | 90.00M | 81.50M | |||
| Marketable Securities | N/A | 62.88M | 29.30M | 83.50M | 211.50M | |||
| Receivables | 14.66M | 17.47M | 16.80M | 57.60M | 69.70M | |||
| Inventories | N/A | N/A | N/A | N/A | N/A | |||
| Other Current Assets | 9.65M | 13.64M | 9.20M | 18.80M | 30.70M | |||
| Total Current Assets | 124.29M | 133.54M | 353.50M | 249.90M | 393.30M | |||
| Non-Current Assets | ||||||||
| PPE Net | 44.08M | 45.35M | 52.00M | 53.30M | 59.70M | |||
| Investments And Advances | N/A | N/A | 0.00 | 67.50M | 12.80M | |||
| Other Non-Current Assets | 202.93M | 203.10M | 201.90M | 4.10M | 3.30M | |||
| Total Non-Current Assets | 247.01M | 248.46M | 253.90M | 124.90M | 75.80M | |||
| TOTAL ASSETS | 371.31M | 382.00M | 607.40M | 374.80M | 469.10M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | N/A | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | N/A | N/A | 0.00 | 16.90M | 19.30M | |||
| Accrued Expenses | N/A | 16.75M | 27.10M | 38.50M | 85.90M | |||
| Accounts Payable | N/A | 1.52M | 1.60M | 3.10M | 6.80M | |||
| Other Current Liabilities | 21.66M | 6.49M | 0.00 | 100.00K | 11.50M | |||
| Total Current Liabilities | 21.66M | 24.77M | 28.70M | 58.60M | 123.60M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | N/A | 0.00 | 0.00 | 599.40M | 599.80M | |||
| Other Non-Current Liabilities | 144.78M | 144.24M | 136.90M | 55.40M | 49.40M | |||
| Total Non-Current Liabilities | 144.78M | 144.24M | 136.90M | 654.80M | 649.20M | |||
| TOTAL LIABILITIES | 166.44M | 169.00M | 165.60M | 713.40M | 772.80M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | N/A | -909.10M | -853.90M | -1.73B | -1.53B | |||
| Additional Paid In Capital | N/A | 1.12B | 1.30B | 1.39B | 1.22B | |||
| Common Shares | N/A | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Shareholders' Equity | 204.87M | -65.00K | 0.00 | 0.00 | 0.00 | |||
| Shares Outstanding | 48.56M | 48.09M | 65.20M | 74.40M | 64.30M | |||
| Tangible Book Value per Share | 4.22 | 4.43 | 6.78 | -4.55 | -4.72 | |||
| Total Shareholders' Equity | 204.87M | 213.00M | 441.80M | -338.60M | -303.80M | |||
| TOTAL LIABILITIES AND EQUITY | 371.31M | 382.00M | 607.40M | 374.80M | 469.10M | |||
| Statistics | ||||||||
| Debt/Equity | N/A | N/A | N/A | -1.77 | -1.97 | |||
| Current Ratio | 5.74 | 5.39 | 12.32 | 4.26 | 3.18 | |||
| Return On Assets (ROA) | -12.06% | -14.45% | 143.58% | -53.20% | -59.26% | |||
| Return On Equity (ROE) | -21.86% | -25.91% | 197.40% | N/A | N/A | |||
All data in USD